Envela ELA 深 沪
等待开盘 11-04 09:30:00 美东时间
9.41
+0.320
+3.52%
华盛通- 最 高9.52
- 今 开9.16
- 成交量 8.17万股
- 最 低 9.1016
- 昨 收 9.09
- 总市值 2.44亿
- 52周最高 9.52
- 市盈率 静 36.46
- 换手率 0.00%
- 52周最低 5.10
- 委 比 -24.24%
- 总股本 2596.53万
- 历史最高 28.57
- 量 比 0.97
- 振 幅 4.60%
- 历史最低 1.33
- 每 手 1
- 风险率 0.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ardelyx Presents Data Supporting Retainagogue, IBSRELA At ACG Annual Scientific Meeting, In Phoenix
IBSRELA patients reported treatment satisfaction in real-world surveyPost-hoc analysis of T3MPO-1 and T3MPO-2 studies demonstrates effectiveness of IBSRELA in reducing abdominal bloating for patients with IBS-CAnalysis
10-28 20:02
华兴资本医疗与生命科技行业周报【Vol.389】
来源：华兴资本 “华兴资本医疗与生命科技行业周报”定期发布，专注从资本角度解读一周数据，并提供最新行业观察。 医疗与生命科技是华兴资本多年来关注并深耕的领域，目...
10-27 09:30
Ardelyx Announces It Will Present New Data Supporting Its Kidney Disease Drug Xphozah At American Society Of Nephrology's Kidney Week 2025 November 5–9 In Houston, Texas
Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced
10-21 20:04
This Palo Alto Networks Analyst Turns Bullish On Improving Checks, Pending CyberArk Acquisition
Analyst Gray Powell upgraded Palo Alto Networks (PANW) to Buy with $248 price target. Field checks show higher adoption and confidence in growth targets.
10-14 00:54
Ardelyx appoints Sue Hohenleitner as CFO
Ardelyx (NASDAQ:ARDX) announced on Monday the appointment of Sue Hohenleitner as Chief Financial Officer (CFO), effective November 4, 2025. Hohenleitner most recently served as the Vice President and...
10-13 21:10
AbbVie's Botox Shows Improvement In Movement Disorder Study
AbbVie's Phase 2 ELATE trial shows onabotulinumtoxinA improves tremor scores and meets all endpoints, offering a new option for essential tremor.
10-06 22:54
AbbVie's BOTOX Meets Primary And All Secondary Endpoints In Phase 2 ELATE Trial For Upper Limb Essential Tremor
OnabotulinumtoxinA (BOTOX®) met the primary endpoint in the Phase 2 trial, demonstrating a statistically significant improvement from baseline in the Tremor Disability Scale-Revised (TREDS-R) total unilateral score
10-06 21:06
K12 Tutoring Strengthens ESSA Validation With New Multi-Grade Results
New Research Builds on Prior ESSA Validation, Demonstrating Broader Student Suc...
09-30 00:00
